Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × TP protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 4 Esophageal Squamous Cell Carcinoma 3 Uterine Cervical Neoplasms 2 Lymphatic Metastasis 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 23 Rituximab 15 Gemcitabine 11 Cisplatin 11 pomalidomide 10 Paclitaxel 10 Lenalidomide 9 Bortezomib 9 Carboplatin 8 Cyclophosphamide 7 carfilzomib 6 Drug Therapy 5 Cytarabine 5 selinexor 4 ibrutinib 4 daratumumab 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 ofatumumab 2 galiximab 2 eculizumab 2 durvalumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01405235 2012-04-12

AGO-Zervix-1

Institut fuer Frauengesundheit

Phase 3 Unknown

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡